Aspire Biopharma Meets $2.5M Equity and $1 Bid Price Compliance
Aspire Biopharma regained compliance with Nasdaq Listing Rule 5550(b)(1) by restoring its minimum stockholders’ equity to $2.5 million and met the $1.00 per share requirement of Listing Rule 5550(a)(2). Nasdaq has confirmed full compliance but will maintain a Panel Monitor until February 18, 2027.
1. Nasdaq Compliance Restored
Aspire Biopharma regained compliance with Nasdaq Listing Rules by restoring its stockholders’ equity above the $2.5 million threshold and meeting the minimum $1.00 per share bid requirement, securing its continued trading on the Nasdaq Stock Market.
2. Panel Monitor Details
Despite regaining full compliance, Nasdaq will maintain a Panel Monitor over the company under Listing Rule 5815(d)(4)(B) for one year through February 18, 2027; failure to sustain the $2.5 million equity requirement during this period will trigger a mandatory hearing without the option to submit a compliance plan.
3. Listing Implications
Maintaining listing status preserves liquidity and investor access, while the ongoing monitoring period highlights the need for Aspire to strengthen its balance sheet; investors will be watching quarterly equity levels to avoid potential delisting proceedings.